lorlatinib — CareFirst (Caremark)
Relapsed or refractory ALK-positive large B-cell lymphoma
Initial criteria
- Diagnosis of relapsed or refractory ALK-positive large B-cell lymphoma
- Used as a single agent
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months